In The News
EPI Health Announces Acquisition by Novan, Inc. to Create Fully Integrated Specialty Dermatology Company
EPI Health Announces Acquisition by Novan, Inc. to Create Fully Integrated Specialty Dermatology Company · Resulting entity to have broad portfolio of commercial product in dermatology and established pipeline of early and late-stage product candidates in...
EPI Health and MC2 Therapeutics Announce Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) now covered on Express Scripts National Preferred Formulary
NEWS PROVIDED BY EPI Health, LLC November 9, 2021, 08:00 ET --- Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. CHARLESTON, SC, USA and...
New Expert Roundtable Publication from National Rosacea Society Emphasizes Importance of Treating Erythema of Rosacea
PRESS RELEASE for distribution August 31, 2021, 08:00 ET Results of an expert roundtable meeting now published in Journal of Drugs in Dermatology concluded that dermatologists need to place greater emphasis on managing persistent facial erythema (or neurovascular...
EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)
PRESS RELEASE for distribution July 19, 2021, 08:00 ET Now available: Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age or older introduces use of PAD™...
Highly Significant Head to Head Data for Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) for the Treatment of Plaque Psoriasis Accepted to Maui Derm Summer Meeting
PRESS RELEASE for distribution July 6, 2021 Two posters featuring highly significant head to head data for Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) vs Taclonex® Topical Suspension were shown at the Maui Derm NPPA Summer meeting...
EPI Health Expands Solid Payor Coverage on Rhofade
NEWS PROVIDED BY EPI Health, LLC November 4, 2020 The formulary at Express Scripts and other major PBMs have expanded coverage to include Rhofade® and other EPI Health Products, bringing coverage to over 145 million US Commercial lives. Rhofade®...
EPI Health Announces Rhofade® (oxymetazoline hydrochloride) cream, 1% is now covered on the Express Scripts National Preferred Formulary
Express Scripts National Preferred Formulary covers approximately 24 million lives --- Rhofade® is the only FDA-approved alpha 1 agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults CHARLESTON, SC,...
MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US
Collaboration accelerates a Q1 2021 comprehensive launch of MC2's WYNZORA® Cream to patients with plaque psoriasis in the US WYNZORA® Cream is the first drug based on PADTM Technology - providing innovative solutions to unmet needs in chronic inflammatory conditions...
EPI Health, LLC Acquires Worldwide Rights to RHOFADE® from Aclaris Therapeutics, Inc.
NEWS PROVIDED BY EPI Health, LLC October 14, 2019, 08:00 ET CHARLESTON, SC, October 14, 2019 /PRNewswire/ -- EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists, today announced that it...
EPI Health, LLC Appoints Brett Fair as Vice President of Commercial Operations and Strategy
CHARLESTON, SC / ACCESSWIRE / September 17, 2019 / EPI Health, LLC, a specialty pharmaceutical company focused on acquiring, developing and marketing prescription medical dermatological products, today announced the appointment of Brett Fair as Vice President of...